Inhalation Sciences appoints Lena Heffler as new CEO
STOCKHOLM, SWEDEN – 19 April, 2018. Inhalation Sciences, who develop and sell world-leading labtech for inhalation research, announces Lena Heffler as its new CEO. Lena officially takes up her new role on 7 May 2018.
Inhalation Sciences (ISAB) develops instruments that accelerate and facilitate the development of inhaled drugs and lung research. The company’s products are currently in the early commercialization phase. Lena Heffler has been appointed to strengthen the company’s focus on sales and marketing. Lena will succeed present CEO Fredrik Sjövall, who will be proposed as the new Chairman of the Board by the company’s main owner at the next Annual General Meeting on 23 May. Lena will take up her new position on May 7.
With an MSc in Biochemistry from Uppsala University and a Licentiate Degree in Clinical Immunology from Karolinska Institutet, Lena Heffler has worked with sales in the life sciences industry for more than 15 years. Her former clients include Agilent, Aerocrine and Addtech.
Otto Skolling, Chairman of the Board: "Lena has a strong, clear background in commercialization in life sciences. Commitment, energy and a strong focus on sales were all important cornerstones in the recruitment of our new CEO. We’re confident Lena has all the qualities needed to take Inhalation Sciences to the next level.”
Lena Heffler, CEO: "Inhalation Sciences is a company with a unique and very exciting technology platform that has the potential to make a huge difference to inhalation researchers the world over. Right now the company is in an exciting phase, with many customer dialogues ongoing and a commercial breakthrough within reach. I have 15 years of experience selling and marketing products and technologies in the life sciences field. I’m looking forward to transferring those skills to the ongoing job of making PreciseInhale the standard instrument in the world's inhalation labs, and Inhalation Sciences a successful, profitable company."
For more information about Inhalation Sciences please contact:
Fredrik Sjövall, CEO
Email: fredrik.sjovall@inhalation.se
Phone: +46 (0)70 64 508 75
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.
The information above was provided by Inhalation Sciences Sweden AB (publ) according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on April 19, 2017.